Increased prevalence of high-risk coronary plaques in metabolic dysfunction associated stetatotic liver disease patients : A meta-analysis
© 2024 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd..
BACKGROUND: Metabolic dysfunction associated steatotic liver disease (MASLD) is associated with an increased risk of coronary artery disease. Computed Tomography Coronary Angiography (CTCA) can assess both the extent and the features of coronary plaques. We aimed to gather evidence about the prevalence and features of coronary plaques among MASLD patients.
METHODS: PubMed, Scopus, and Google Scholar databases were searched for randomized controlled trials and adjusted observational studies assessing the prevalence and features of coronary plaques by means of CTCA in MASLD patients as compared with a control group. The prevalence of coronary stenosis (defined as >30% and >50% diameter of stenosis), of increasing coronary artery calcium (CAC) score and of high-risk features (namely low-attenuation plaques, napkin ring sign, spotty calcification and positive remodelling) in MASLD patients were the endpoints of interest.
RESULTS: Twenty-four observational studies were included. MASLD was associated with an increased prevalence of critical coronary stenosis compared with controls (odds ratio [OR] 1.54, 95%CI 1.23-1.93). Increased values of CAC score were observed in MASLD patients (OR 1.35, 95%CI 1.02-1.78 and OR 2.26, 95%CI 1.57-3.23 for CAC score 0-100 and >100, respectively). An increased risk of 'high-risk' coronary plaques was observed in MASLD patients (OR 2.13, 95%CI 1.42-3.19). As high-risk features plaques, a higher prevalence of positive remodelling and spotty calcification characterize MASLD patients (OR 2.92, 95%CI 1.79-4.77 and OR 2.96, 95%CI 1.22-7.20).
CONCLUSIONS: Patients with MASLD are at increased risk of developing critical coronary stenosis and coronary plaques characterized by high-risk features as detected by CTCA.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
European journal of clinical investigation - (2024) vom: 23. Feb., Seite e14188 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
De Filippo, Ovidio [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Atherosclerosis |
|---|
| Anmerkungen: |
Date Revised 24.02.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1111/eci.14188 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368863387 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368863387 | ||
| 003 | DE-627 | ||
| 005 | 20240229150840.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/eci.14188 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1304.xml |
| 035 | |a (DE-627)NLM368863387 | ||
| 035 | |a (NLM)38396359 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a De Filippo, Ovidio |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Increased prevalence of high-risk coronary plaques in metabolic dysfunction associated stetatotic liver disease patients |b A meta-analysis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 24.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2024 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd. | ||
| 520 | |a BACKGROUND: Metabolic dysfunction associated steatotic liver disease (MASLD) is associated with an increased risk of coronary artery disease. Computed Tomography Coronary Angiography (CTCA) can assess both the extent and the features of coronary plaques. We aimed to gather evidence about the prevalence and features of coronary plaques among MASLD patients | ||
| 520 | |a METHODS: PubMed, Scopus, and Google Scholar databases were searched for randomized controlled trials and adjusted observational studies assessing the prevalence and features of coronary plaques by means of CTCA in MASLD patients as compared with a control group. The prevalence of coronary stenosis (defined as >30% and >50% diameter of stenosis), of increasing coronary artery calcium (CAC) score and of high-risk features (namely low-attenuation plaques, napkin ring sign, spotty calcification and positive remodelling) in MASLD patients were the endpoints of interest | ||
| 520 | |a RESULTS: Twenty-four observational studies were included. MASLD was associated with an increased prevalence of critical coronary stenosis compared with controls (odds ratio [OR] 1.54, 95%CI 1.23-1.93). Increased values of CAC score were observed in MASLD patients (OR 1.35, 95%CI 1.02-1.78 and OR 2.26, 95%CI 1.57-3.23 for CAC score 0-100 and >100, respectively). An increased risk of 'high-risk' coronary plaques was observed in MASLD patients (OR 2.13, 95%CI 1.42-3.19). As high-risk features plaques, a higher prevalence of positive remodelling and spotty calcification characterize MASLD patients (OR 2.92, 95%CI 1.79-4.77 and OR 2.96, 95%CI 1.22-7.20) | ||
| 520 | |a CONCLUSIONS: Patients with MASLD are at increased risk of developing critical coronary stenosis and coronary plaques characterized by high-risk features as detected by CTCA | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a atherosclerosis | |
| 650 | 4 | |a computed tomography coronary angiography | |
| 650 | 4 | |a coronary artery disease | |
| 650 | 4 | |a coronary plaques | |
| 650 | 4 | |a metabolic-associated steatotic liver disease | |
| 700 | 1 | |a Di Pietro, Gianluca |e verfasserin |4 aut | |
| 700 | 1 | |a Nebiolo, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Ribaldone, Davide Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Gatti, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Bruno, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Gallone, Guglielmo |e verfasserin |4 aut | |
| 700 | 1 | |a Armandi, Angelo |e verfasserin |4 aut | |
| 700 | 1 | |a Birtolo, Lucia Ilaria |e verfasserin |4 aut | |
| 700 | 1 | |a Zullino, Veronica |e verfasserin |4 aut | |
| 700 | 1 | |a Mennini, Gianluca |e verfasserin |4 aut | |
| 700 | 1 | |a Corradini, Stefano Ginanni |e verfasserin |4 aut | |
| 700 | 1 | |a Mancone, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Bugianesi, Elisabetta |e verfasserin |4 aut | |
| 700 | 1 | |a Iannaccone, Mario |e verfasserin |4 aut | |
| 700 | 1 | |a De Ferrari, Gaetano Maria |e verfasserin |4 aut | |
| 700 | 1 | |a D'Ascenzo, Fabrizio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of clinical investigation |d 1970 |g (2024) vom: 23. Feb., Seite e14188 |w (DE-627)NLM000003107 |x 1365-2362 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:23 |g month:02 |g pages:e14188 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/eci.14188 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 23 |c 02 |h e14188 | ||